Spots Global Cancer Trial Database for xeroderma pigmentosum
Every month we try and update this database with for xeroderma pigmentosum cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy | NCT00001813 | Cockayne Syndro... Skin Neoplasms Xeroderma Pigme... Trichothiodystr... Genodermatosis | 6 Weeks - | National Institutes of Health Clinical Center (CC) | ||
| A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP) | NCT05159752 | Xeroderma Pigme... | Afamelanotide | 18 Years - 75 Years | Clinuvel Pharmaceuticals Limited | |
| Xeroderma Pigmentosum Patient Experiences | NCT01123694 | Xeroderma Pigme... | Survey Study | - | Henry Ford Health System | |
| Natural History Study for DNA Repair Disorders | NCT05484570 | DNA Repair Diso... Cockayne Syndro... Xeroderma Pigme... Trichothiodystr... | Interval Histor... Physical Examin... ECAB Assessment Gait Assessment Specimen Sample... | 6 Months - | University of Minnesota | |
| A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V | NCT05370235 | Xeroderma Pigme... | Afamelanotide | 18 Years - 75 Years | Clinuvel Pharmaceuticals Limited | |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | NCT04500548 | Constitutional ... Hematopoietic a... Lynch Syndrome Recurrent Lymph... Recurrent Malig... Recurrent Neuro... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Neur... Refractory Prim... Xeroderma Pigme... | Biospecimen Col... Ipilimumab Nivolumab | 12 Months - 25 Years | National Cancer Institute (NCI) | |
| Reproductive Options in Inherited Skin Diseases | NCT06330324 | Ichthyosis Palmoplantar Ke... Epidermolysis B... Ectodermal Dysp... Basal Cell Nevu... Birt-Hogg-Dube ... Tuberous Sclero... Xeroderma Pigme... Cutis Laxa Albinism | - | Maastricht University Medical Center | ||
| XPAND Trial: Enhancing XP Photoprotection Activities - New Directions | NCT03445052 | Xeroderma Pigme... | XPAND | 16 Years - | Guy's and St Thomas' NHS Foundation Trust | |
| Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum | NCT00046189 | Xeroderma Pigme... Basal Cell Carc... Squamous Cell C... Melanoma Skin Cancer | 1 Month - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V | NCT05370235 | Xeroderma Pigme... | Afamelanotide | 18 Years - 75 Years | Clinuvel Pharmaceuticals Limited | |
| Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum | NCT00046189 | Xeroderma Pigme... Basal Cell Carc... Squamous Cell C... Melanoma Skin Cancer | 1 Month - 99 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
